Cyclosporine for Severe Drug Eruption in a Psoriasis Patient

Main Article Content

Sarina Singer
Research assistant, Icahn School of Medicine at Mount Sinai, New York, NY

Nahla Shihab
Clinical Dermatology Fellow, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Mark Lebwohl
Professsor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Keywords

cyclosporine, psoriasis, drug eruption

Abstract

Abstract not available.

References

1. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.

2. Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4:411.

3. Bircher AJ. Exanthematous (maculopapular) drug eruption. [Updated 2018 May 22]. In: UpToDate [Internet]. Available from: https://www.uptodate.com/contents/exanthematous-drug-eruption (accessed 11 November 2019).

4. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, et al. Guidelies of care for the management of psoriasis and psoriasis arthritis. J Am Acad Dermatol. 2011 Jul;65(1):137-74.

5. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction. J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1022-5

6. Hardinger K, Magee CC. Pharmacology of cyclosporine and tacrolimus. [Updated 2018 April 25]. In: UpToDate [Internet]. Available from: https://www.uptodate.com/contents/pharmacology-of-cyclosporine-and-tacrolimus (accessed 11 November 2019).

Article Sidebar

PDF
Published
Jul 12, 2020
DOI https://doi.org/10.25251/skin.4.4.23

Article Details

How to Cite
[1]
Singer, S., Shihab, N. and Lebwohl, M. 2020. Cyclosporine for Severe Drug Eruption in a Psoriasis Patient. SKIN The Journal of Cutaneous Medicine. 4, 4 (Jul. 2020), 388–389. DOI:https://doi.org/10.25251/skin.4.4.23.
Issue
Vol. 4 No. 4 (2020)
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>